Your browser doesn't support javascript.
loading
Circulating plasma phospholipid fatty acids and risk of pancreatic cancer in a large European cohort.
Matejcic, M; Lesueur, F; Biessy, C; Renault, A L; Mebirouk, N; Yammine, S; Keski-Rahkonen, P; Li, K; Hémon, B; Weiderpass, E; Rebours, V; Boutron-Ruault, M C; Carbonnel, F; Kaaks, R; Katzke, V; Kuhn, T; Boeing, H; Trichopoulou, A; Palli, D; Agnoli, C; Panico, S; Tumino, R; Sacerdote, C; Quirós, J R; Duell, E J; Porta, M; Sánchez, M J; Chirlaque, M D; Barricarte, A; Amiano, P; Ye, W; Peeters, P H; Khaw, K T; Perez-Cornago, A; Key, T J; Bueno-de-Mesquita, H B; Riboli, E; Vineis, P; Romieu, I; Gunter, M J; Chajès, V.
Afiliação
  • Matejcic M; International Agency for Research on Cancer, Lyon, France.
  • Lesueur F; Genetic Epidemiology of Cancer team, Inserm, U900, Paris, France.
  • Biessy C; Institut Curie, Paris, France.
  • Renault AL; PSL University, Paris, France.
  • Mebirouk N; Mines ParisTech, Fontainebleau, France.
  • Yammine S; International Agency for Research on Cancer, Lyon, France.
  • Keski-Rahkonen P; Genetic Epidemiology of Cancer team, Inserm, U900, Paris, France.
  • Li K; Institut Curie, Paris, France.
  • Hémon B; PSL University, Paris, France.
  • Weiderpass E; Mines ParisTech, Fontainebleau, France.
  • Rebours V; Genetic Epidemiology of Cancer team, Inserm, U900, Paris, France.
  • Boutron-Ruault MC; Institut Curie, Paris, France.
  • Carbonnel F; PSL University, Paris, France.
  • Kaaks R; Mines ParisTech, Fontainebleau, France.
  • Katzke V; International Agency for Research on Cancer, Lyon, France.
  • Kuhn T; International Agency for Research on Cancer, Lyon, France.
  • Boeing H; International Agency for Research on Cancer, Lyon, France.
  • Trichopoulou A; International Agency for Research on Cancer, Lyon, France.
  • Palli D; Genetic Epidemiology Group, Folkhälsan Research Center, Helsinki, Finland.
  • Agnoli C; Department of Community Medicine, Faculty of Health Sciences, University of Tromsø - The Arctic University of Norway, Tromsø, Norway.
  • Panico S; Department of Research, Cancer Registry of Norway, Institute of Population-Based Cancer Research, Oslo, Norway.
  • Tumino R; Public Health Division of Gipuzkoa, BioDonostia Research institute, San Sebastian, Spain.
  • Sacerdote C; Department of Gastroenterology and Pancreatology, Beaujon Hospital, University Paris 7, Clichy, France.
  • Quirós JR; INSERM, Centre for Research in Epidemiology and Population Health, U1018, Health across Generations Team, Institut Gustave Roussy, Villejuif, France.
  • Duell EJ; Université Paris Sud, UMRS, Villejuif, France.
  • Porta M; INSERM, Centre for Research in Epidemiology and Population Health, U1018, Health across Generations Team, Institut Gustave Roussy, Villejuif, France.
  • Sánchez MJ; Université Paris Sud, UMRS, Villejuif, France.
  • Chirlaque MD; Department of Gastroenterology, Bicêtre University Hospital, Assistance Publique des Hôpitaux de Paris, Le Kremlin Bicêtre, France.
  • Barricarte A; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Amiano P; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Ye W; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Peeters PH; Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Nuthetal, Germany.
  • Khaw KT; Hellenic Health Foundation, Athens, Greece.
  • Perez-Cornago A; WHO Collaborating Center for Nutrition and Health, Unit of Nutritional Epidemiology and Nutrition in Public Health, Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Athens, Greece.
  • Key TJ; Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute - ISPO, Florence, Italy.
  • Bueno-de-Mesquita HB; Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Riboli E; Clinical Medicine and Surgery Department, Università degli Studi di Napoli Federico II, Naples, Italy.
  • Vineis P; Cancer Registry and Histopathology Department, ASP, "Civic - M.P. Arezzo" Hospital, Ragusa, Italy.
  • Romieu I; Unit of Cancer Epidemiology, Citta' della Salute e della Scienza Hospital, University of Turin and Centre for Cancer Prevention (CPO), Turin, Italy.
  • Gunter MJ; EPIC Asturias, Public Health Directorate, Asturias, Spain.
  • Chajès V; Unit of Nutrition and Cancer, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain.
Int J Cancer ; 143(10): 2437-2448, 2018 11 15.
Article em En | MEDLINE | ID: mdl-30110135
ABSTRACT
There are both limited and conflicting data on the role of dietary fat and specific fatty acids in the development of pancreatic cancer. In this study, we investigated the association between plasma phospholipid fatty acids and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. The fatty acid composition was measured by gas chromatography in plasma samples collected at recruitment from375 incident pancreatic cancer cases and375 matched controls. Associations of specific fatty acids with pancreatic cancer risk were evaluated using multivariable conditional logistic regression models with adjustment for established pancreatic cancer risk factors. Statistically significant inverse associations were found between pancreatic cancer incidence and levels of heptadecanoic acid (ORT3-T1 [odds ratio for highest versus lowest tertile] =0.63; 95%CI[confidence interval] = 0.41-0.98; ptrend = 0.036), n-3 polyunsaturated α-linolenic acid (ORT3-T1 = 0.60; 95%CI = 0.39-0.92; ptrend = 0.02) and docosapentaenoic acid (ORT3-T1 = 0.52; 95%CI = 0.32-0.85; ptrend = 0.008). Industrial trans-fatty acids were positively associated with pancreatic cancer risk among men (ORT3-T1 = 3.00; 95%CI = 1.13-7.99; ptrend = 0.029), while conjugated linoleic acids were inversely related to pancreatic cancer among women only (ORT3-T1 = 0.37; 95%CI = 0.17-0.81; ptrend = 0.008). Among current smokers, the long-chain n-6/n-3 polyunsaturated fatty acids ratio was positively associated with pancreatic cancer risk (ORT3-T1 = 3.40; 95%CI = 1.39-8.34; ptrend = 0.007). Results were robust to a range of sensitivity analyses. Our findings suggest that higher circulating levels of saturated fatty acids with an odd number of carbon atoms and n-3 polyunsaturated fatty acids may be related to lower risk of pancreatic cancer. The influence of some fatty acids on the development of pancreatic cancer may be sex-specific and modulated by smoking.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2018 Tipo de documento: Article